Journal
JOURNAL OF REHABILITATION MEDICINE
Volume 37, Issue 6, Pages 358-364Publisher
FOUNDATION REHABILITATION INFORMATION
DOI: 10.1080/16501970510038365
Keywords
erectile dysfunction; spinal cord injury; cost-utility analysis
Categories
Ask authors/readers for more resources
Background: There is a high incidence of erectile dysfunction after spinal cord injury. This can have a profound effect on quality of life. Treatment options for erectile dysfunction include sildenafil, intracavernous injections of papaverine/ alprostadil (Caverject(R)), alprostadil/ papaverine/ phentolamine (Triple Mix), transurethral suppository (MUSE(R)), surgically implanted prosthetic device and vacuum erection devices. However, physical impairments and accessibility may preclude patient self-utilization of non-oral treatments. Methods: The costs and utilities of oral and non-oral erectile dysfunction treatments in a spinal cord injury population were examined in a cost-utility analysis conducted from a government payer perspective. Subjects with spinal cord injury (n = 59) reported health preferences using the standard gamble technique. Results: There was a higher health preference for oral therapy. The cost-effectiveness results indicated that sildenafil was the dominant economic strategy when compared with surgically implanted prosthetic devices, MUSE(R) and Caverject(R). The incremental cost-utility ratios comparing sildenafil with triple mix and vacuum erection devices favoured sildenafil, with ratios less than CAN$20,000 per quality adjusted life year gained. Conclusion: Based on this study, we conclude that sildenafil is a cost-effective treatment for erectile dysfunction in the spinal cord injury population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available